Biogen believes biosimilars are important to safeguarding future healthcare innovation. Biosimilars can alleviate some of the burden on healthcare systems by offering cost savings and promoting earlier and sustainable access to therapies. Biosimilars can also expand options for patients and physicians to meet individual needs.
Biosimilars offer a range of benefits to multiple stakeholders, enabling a balance of bringing innovative drugs to areas of unmet need, maintaining choice and access for patients and providers, and providing potential savings to the healthcare system.
Biosimilars are medicines that are highly similar1 to currently available biologic therapies, known as “reference medicines”. Yet biosimilars are unique — they offer the potential to expand patient access to life-changing biologic therapies while generating healthcare sustainability with meaningful cost savings for society. Biosimilars can also expand options for patients and physicians to meet individual needs with greater treatment choice and relevant product or service differentiation.